When given as a first-line therapy, Libtayo (cemiplimab) prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC), compared with platinum-based chemotherapy, according to early data from a Phase 3 trial. In addition to improving survival, Libtayo increased the proportion of people who responded to treatment, and lowered their risk of death or…

October is Breast Cancer Awareness Month, set aside annually to bring attention to the disorder and the community’s needs. From sharing photographs and educational resources, to hosting virtual fundraisers and wearing pink ribbons, supporters already are observing the month-long event. “Twenty-twenty [2020] has been a powerful reminder that we are all in this together, and our…

Relugolix, a form of hormone therapy for prostate cancer, has failed to significantly extend the time men with advanced disease live without acquiring resistance to castration medications, compared with standard-of-care leuprolide acetate, updated findings from the HERO trial show. While the trial (NCT03085095) had met its primary goal of increasing the proportion of patients achieving…

Fertility-sparing surgery can effectively treat borderline ovarian tumors (BOTs), while preserving a woman’s ability to conceive and bear children, a new study suggests. The study, “Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study,” was published in Fertility and…

The navigation platform HealthTree has added a feature that enables people with myeloma to communicate with other patients on specific disease topics. Called Myeloma Crowd Community Forums, the feature organizes forums by topics that can be easily found. Patients may toggle among posts, pose questions, and have chats with other patients. “Facebook groups are often a patient’s…

Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer, and also significantly lowers their risk of disease progression or death, according to interim data from a Phase 3 trial. Notably, these benefits were seen across multiple patient subgroups, regardless of…

First-line treatment with Keytruda (pembrolizumab) continues to promote significant survival benefits and durable responses in people with metastatic non-small cell lung cancer (NSCLC) and high levels of PD-L1, compared with standard chemotherapy, according to five-year data from the KEYNOTE-024 Phase 3 clinical trial. The results showed that twice as many Keytruda-treated patients were alive at five years,…

Nearly all men with non-metastatic castration-resistant prostate cancer (nmCRPC) received the full planned dose of Nubeqa (darolutamide) tablets while participating in the ARAMIS Phase 3 trial, and few required dose adjustments or discontinued treatment, according to a new ad-hoc analysis of the study. Findings from this analysis were recently presented in an e-poster, titled “Tolerability…

Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients receiving a dose of 2.9 mg/kg or higher responded to this investigational antibody-drug conjugate, and nearly half (44%) had responses lasting at least 16 weeks, results showed.…

ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma. Under the agreement, The Binding Site has gained exclusive rights to commercialize this test worldwide. ONCOTracker, which has patented…

When given alongside endocrine therapy (ET), Verzenio (abemaciclib) can lower the risk of cancer recurrence and spread compared to standard ET alone in patients with certain forms of early breast cancer who have a high risk of seeing their disease return and spread elsewhere, according to results from a Phase 3 trial. Data from the study’s…

Adding Takeda’s Ninlaro (ixazomib) to Revlimid (lenalidomide) and dexamethasone failed to significantly extend life without disease progression in people newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplant, top-line data from a Phase 3 clinical trial show. Still, Ninlaro’s triple combination was significantly superior to the Revlimid-dexamethasone combo at promoting profound treatment…